Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multi-centre, randomized, double-blind, double-dummy, multiple-dose, crossover study to evaluate the pharmacodynamics, pharmacokinetics, safety and tolerability of orally inhaled indacaterol administered as either PulmoSphere or lactose-blend powder via the Concept1 device in adult patients with persistent asthma.

X
Trial Profile

A multi-centre, randomized, double-blind, double-dummy, multiple-dose, crossover study to evaluate the pharmacodynamics, pharmacokinetics, safety and tolerability of orally inhaled indacaterol administered as either PulmoSphere or lactose-blend powder via the Concept1 device in adult patients with persistent asthma.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Apr 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Indacaterol (Primary) ; Indacaterol (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Jun 2012 Actual end date (22 May 2012) added as reported by European Clinical Trials Database record.
    • 23 Jun 2012 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
    • 01 Dec 2011 Planned number of patients added as 36.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top